Avacta targets South East Asia and Pacific

DIAGNOSTICS specialist Avacta Group has agreed a new partnership deal which will see it expand into the South East Asia and Pacific markets.

US firm Pall Corporation will sell Avacta’s Optim device in countries including South Korea, Australia, New Zealand and Singapore.

Optim is used by pharmaceutical developers to help develop new drugs.

Hide Ad
Hide Ad

Alastair Smith, chief executive of Wetherby-based Avacta, said: “We are delighted to expand our collaboration with Pall further and to benefit from their expertise and resources in the South East Asian market.

“We are very pleased with the progress that Pall are making with Optim sales and marketing in North America and expect to see the same sort of progress in this new territory.

“The strengthening of our commercial partnership with Pall through the development of a joint analytical services offering, that was recently announced, and potential to develop new products together is very important to Avacta and we anticipate that this will provide a strong platform for growth in this area of the Group’s activities.”

Ken Frank, senior vice-president of Pall Corporation and president of Pall’s biopharmaceutical division, added: “The extension of our collaboration with Avacta in South East Asia complements our investments in this area and significantly furthers our capability to provide high value, differentiated solutions to the developers and manufacturers of biomolecules for global healthcare needs.”

Related topics: